183 related articles for article (PubMed ID: 11258618)
1. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
5. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
[TBL] [Abstract][Full Text] [Related]
6. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
8. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
[TBL] [Abstract][Full Text] [Related]
9. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues.
Butler M; Stecker K; Bennett CF
Lab Invest; 1997 Oct; 77(4):379-88. PubMed ID: 9354772
[TBL] [Abstract][Full Text] [Related]
10. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue.
Geary RS; Matson J; Levin AA
Anal Biochem; 1999 Oct; 274(2):241-8. PubMed ID: 10527522
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
12. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes.
Yu RZ; Geary RS; Leeds JM; Watanabe T; Fitchett JR; Matson JE; Mehta R; Hardee GR; Templin MV; Huang K; Newman MS; Quinn Y; Uster P; Zhu G; Working PK; Horner M; Nelson J; Levin AA
Pharm Res; 1999 Aug; 16(8):1309-15. PubMed ID: 10468036
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
16. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
Soucy NV; Riley JP; Templin MV; Geary R; de Peyster A; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2006 Feb; 77(1):22-8. PubMed ID: 16496297
[TBL] [Abstract][Full Text] [Related]
17. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
18. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.
Cossum PA; Sasmor H; Dellinger D; Truong L; Cummins L; Owens SR; Markham PM; Shea JP; Crooke S
J Pharmacol Exp Ther; 1993 Dec; 267(3):1181-90. PubMed ID: 8166890
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
Wu D; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
[TBL] [Abstract][Full Text] [Related]
20. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.
Graham MJ; Crooke ST; Monteith DK; Cooper SR; Lemonidis KM; Stecker KK; Martin MJ; Crooke RM
J Pharmacol Exp Ther; 1998 Jul; 286(1):447-58. PubMed ID: 9655890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
